Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
Completed · Phase 3 · NCT02632175
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $6,100
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 59
About the trial
- Sponsor
- AbbVie
- Tested
- Adalimumab (biological)
- Dates
- Started 2015-11-26; completion 2025-04-08
- Results posted
- Yes
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
From ClinicalTrials.gov, last updated 2025-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $6,100 in research payments for this study in 2025 (5 payments).
Products named: Rinvoq, Humira
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Minnesota Gastroenterology PA $5,891
- Minnesota Gastroenterology $209
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.